CD8A and neoplasm: Thus, development of new quantitative approaches such as the TOMAHAQ-targeted MS [9] are needed to correlate the amount of presented neoantigens and CD8 T cell-induced anti-tumor efficacy, especially for comparing sources of neoantigens.